| Literature DB >> 29956105 |
Bin-Lu Sun1, Wei-Wei Li1, Chi Zhu1, Wang-Sheng Jin1, Fan Zeng1, Yu-Hui Liu1, Xian-Le Bu1, Jie Zhu1, Xiu-Qing Yao2, Yan-Jiang Wang3,4.
Abstract
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are currently available. During the past year, significant progress has been made in clinical research on the diagnosis, prevention, and treatment of AD. In this review, we summarize the latest achievements, including diagnostic biomarkers, polygenic hazard score, amyloid and tau PET imaging, clinical trials targeting amyloid-beta (Aβ), tau, and neurotransmitters, early intervention, and primary prevention and systemic intervention approaches, and provide novel perspectives for further efforts to understand and cure the disease.Entities:
Keywords: 5-HT6 receptor antagonist; Alzheimer’s disease; Amyloid-beta; BACE1 inhibitor; Biomarker; Immunotherapy; Positron emission tomographic imaging; Primary prevention; Tau
Mesh:
Substances:
Year: 2018 PMID: 29956105 PMCID: PMC6246849 DOI: 10.1007/s12264-018-0249-z
Source DB: PubMed Journal: Neurosci Bull ISSN: 1995-8218 Impact factor: 5.203